Loading...
XSWX
BION
Market cap1.75bUSD
Apr 04, Last price  
27.55CHF
1D
-4.84%
1Q
-24.83%
Jan 2017
-50.00%
IPO
54.08%
Name

BB Biotech AG

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
7.26%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
0.85%
Revenues
-200m
L-43.18%
213,657,000332,660,000318,065,000073,820,00054,293,0001,578,000-1,269,000376,820,000937,893,0001,476,387,000659,227,000-796,446,000693,053,000-465,753,000685,238,000699,233,000-396,220,000-351,227,000-199,567,000
Net income
-207m
L-42.26%
202,752,000317,993,000297,395,000-265,411,00045,353,00036,626,000-146,348,000-65,138,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000677,431,000691,174,000-404,808,000-357,812,000-206,607,000
CFO
218m
P
107,318,000-6,141,000-19,804,000201,017,000509,390,000167,838,000-23,411,000169,521,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000215,021,000262,449,000-94,787,000-357,812,000218,276,000
Dividend
Mar 25, 20242 CHF/sh
Earnings
Apr 24, 2025

Profile

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
URL
https://www.bbbiotech.ch/
IPO date
Nov 08, 2006
Employees
10
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
(199,567)
-43.18%
(351,227)
-11.36%
Cost of revenue
5,794
5,430
Unusual Expense (Income)
NOPBT
(205,361)
(356,657)
NOPBT Margin
102.90%
101.55%
Operating Taxes
79
61
Tax Rate
NOPAT
(205,440)
(356,718)
Net income
(206,607)
-42.26%
(357,812)
-11.61%
Dividends
(156,311)
(212,242)
Dividend yield
6.67%
6.94%
Proceeds from repurchase of equity
(27,303)
BB yield
0.89%
Debt
Debt current
363,000
Long-term debt
363,000
Deferred revenue
Other long-term liabilities
(363,000)
Net debt
(5,269,929)
(2,327,297)
Cash flow
Cash from operating activities
218,276
(357,812)
CAPEX
Cash from investing activities
588,943
Cash from financing activities
(220,213)
(233,271)
FCF
2,841,747
231,753
Balance
Cash
2,635,215
1,948
Long term investments
2,634,714
3,051,349
Excess cash
5,279,907
3,070,858
Stockholders' equity
2,359,725
2,722,643
Invested Capital
260,772
326,381
ROIC
ROCE
EV
Common stock shares outstanding
54,846
55,364
Price
42.75
-22.55%
55.20
-28.45%
Market cap
2,344,666
-23.28%
3,056,075
-28.45%
EV
(2,925,262)
728,778
EBITDA
(205,361)
(356,657)
EV/EBITDA
14.24
Interest
5,802
1,726
Interest/NOPBT